Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Napabucasin + Panitumumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Napabucasin | BB608|BBI608|BBI-608|GB201|GB-201|GB 201 | STAT3 Inhibitor 26 | Napabucasin (BBI608) is a small molecule inhibitor of cancer stemness that reduces activated Stat3 signaling, which is often activated by FGFRs, thereby decreasing proliferation of cancer stem cells, and possibly resulting in decreased cancer metastasis (PMID: 25605917, PMID: 23935373, PMID: 32694160). | |
Panitumumab | Vectibix | ABX-EGF | EGFR Antibody 61 | Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01776307 | Phase II | Cetuximab + Napabucasin Capecitabine + Napabucasin Napabucasin + Panitumumab | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | Completed | USA | 0 |